---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-116764"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:43:50.021161+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Ironwood CBO Andrew Davis resigns effective Nov 22, 2024

## Summary
- Andrew Davis resigns as Senior Vice President, Chief Business Officer.
- Resignation effective November 22, 2024; no replacement announced.
- Davis notified company on November 6, 2024; reason not disclosed.

## SEC filing metadata
- accession: 0001104659-24-116764
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465924116764/0001104659-24-116764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465924116764/tm2428178d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-116764
- JSON: https://secwatch.observer/filing/0001104659-24-116764.json
- Plain text: https://secwatch.observer/filing/0001104659-24-116764.txt

## Key facts
- Executive change
  Andrew Davis departed as Senior Vice President, Chief Business Officer at IRONWOOD PHARMACEUTICALS INC.
  - Action: resigning
  - Role: Senior Vice President, Chief Business Officer
  source text: Andrew Davis notified Ironwood Pharmaceuticals, Inc. (the “Company”) that he is resigning from his position as Senior Vice President, Chief Business Officer, effective November 22, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465924116764/0001104659-24-116764-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.